WCG, a provider of solutions that measurably improve the quality and efficiency of clinical research, agreed to acquire VeraSci, a clinical research company offering eClinical software, translation services, and expertise in endpoints and assessments. Financial terms were not disclosed. "WCG's acquisition of VeraSci represents a natural next step and an exciting growth opportunity. On behalf of WCG, I'm proud to welcome VeraSci, an organization that shares our dedication to improving the clinical trial experience for patients and sites, commitment to scientific rigor and passion for bringing novel technologies into clinical trial processes. This is a marriage of two premier global teams with a common vision," Donald A. Deieso, WCG Executive Chairman and CEO